Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Vertex’s effort to provide fertility support services to those on government insurance programs who want to take the ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

The Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has announced the ...

Vertex Pharmaceuticals is a global biotechnology ... a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting ...

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX Stock Outperforms Industry Image Source: Zacks Investment Research The ...

Vertex Pharmaceuticals Incorporated's stock has ... for its CRISPR/Cas9 gene therapy Casgevy, in patients with Sickle Cell Disease (“SCD”), and a few months later, for patients with ...

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...